Midgard Science
B

Baopharma 宝济药业

Shanghai, Chinabaopharma.comFrom their website, Nov 2026

  • GMP

Work here? Claim this listing

About

Baopharma 宝济药业 develops recombinant protein and antibody-based therapeutics. It works on industrialization and commercialization of these products for patients, with operations in Shanghai and Suzhou, China.

Services

  • Recombinant human hyaluronidase solutions

    Develops recombinant human hyaluronidase for subcutaneous drug delivery and combination use with small molecules and biologics.

  • Recombinant IgG cleaving enzyme development

    Develops an IgG-degrading enzyme platform for rapidly cleaving circulating and tissue IgG in conditions such as autoimmune disease, transplantation, and gene therapy.

  • Recombinant chymotrypsin products

    Develops recombinant chymotrypsin using genetic engineering to replace traditional animal organ extraction methods.

  • Biopharmaceutical manufacturing

    Builds cGMP-compliant manufacturing for drug substance and finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes.

  • Drug substance production

    Operates production lines using mammalian cell expression systems and bacterial/yeast expression systems.

  • Recombinant chymotrypsin development

    Uses genetic engineering to develop chymotrypsin products as an alternative to traditional animal organ extraction methods.

  • Bispecific antibody formulation development

    Develops KJ015, an anti-HER2 bispecific antibody formulated with Hysorptase for subcutaneous administration.

  • Biologics manufacturing

    Manufactures therapeutic biological products using mammalian cell expression systems and bacterial/yeast expression systems.

2 more services
  • Finished dosage form production
  • Clinical development support
Turnaround
Within 1 to 2 hours
What to send
  • Contact mailbox
  • Contact number
  • Message content

Capabilities

Assays and studies
  • Antibodies
  • Bispecifics
  • Small molecules
  • Mammalian expression
  • Lyophilization
  • Clinical trials
  • Phase I clinical trials
Scale and capacity
  • Approximately 63,000 square meters
  • 94 mu
  • 25,000-square-meter facility
  • Approximately 63,000 square meters facility
  • 94 mu (approx. 15.5 acres) of land
Therapeutic areas
  • Autoimmune diseases
  • Rare diseases
  • Organ transplantation
  • Gene therapy
  • Solid tumors
  • IgG-type multiple myeloma
5 more
  • Kidney transplantation
  • Anti-GBM disease
  • Kidney transplant
  • HER2-positive cancers
  • Multiple myeloma

Modalities and species

Modalities
  • Small molecule
  • Antibody
  • Bispecific
  • Recombinant protein
Species and models
  • Mammalian cell expression systems
  • Bacterial expression systems
  • Yeast expression systems
  • Streptococcus pyogenes

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

    Scope: manufacturing facility

Industries served

  • Biotech
  • Pharmaceuticals

Company

Type
CDMO
Founded
2011

Locations

Address
50 Luoxin Road from Shanghai Jingfeng Pharmaceutical Co., Ltd. in October 2021
Sites
Suzhou, China
Serves
China, New Zealand, Europe

Contacts

Similar labs